Skip to content

News & Events

The Global Synthetic Biology Conference

    May 6-9, 2024 | Booth #312
    San Jose Convention Center

    We look forward to meeting you at the Global Synthetic Biology meeting (formerly SynBioBeta). Visit us at booth #312 to explore Ansa’s groundbreaking enzymatic DNA synthesis technology. Don’t miss Ansa’s Chief Scientific Officer, Dan Lin-Arlow, presenting ‘Reshaping Biology with the Power of Enzymatic DNA Synthesis’ in a Spotlight session. Join our interactive Breakout session where industry thought leaders will share their thoughts on the future of DNA synthesis, where innovation intersects with practical solutions to rapidly and reliably synthesize long DNA without sequence limitations. The session will include a panel discussion and Q&A. Join us in unlocking the potential of enzymatic DNA synthesis to revolutionize your research.

    Ansa Biotechnologies Appoints Jason T. Gammack as CEO

      Gammack is joining the company as it completes its early access program and prepares for a full commercial launch of its rapid enzymatic synthesis for complex clonal genes and gene fragments. Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer.

      View the press release.

      6th Annual CRISPR AgBio Conference

        Feb 20-22
        Raleigh, NC

        Join us at this event where Ansa representatives will be actively networking. We look forward to connect with you, answer your questions and discuss options for fulfilling your DNA synthesis requirements. Let’s meet and explore how Ansa can support your specific complex DNA needs.

        Long DNA for Difficult Applications – Dan Lin-Arlow, CEO

          CEO Dan Lin-Arlow discusses Ansa’s groundbreaking de novo synthesis of the world’s longest oligo and their proprietary method in a podcast with Theral Timpson on the Mendelspod podcast. Explore the challenges of synthesizing long DNA, the impact of computation and AI in DNA synthesis, and more. Subscribe to Mendelspod to listen to the full podcast.

          Ansa Biotechnologies Announces First Shipments of Complex Clonal DNA Sequences to Customers in its Early Access Program

            Ansa successfully synthesized and delivered challenging promoter sequences with high GC and AT content to its first Early Access customer, Enoda, which were used to engineer gene expression. Ansa’s proprietary next-generation enzymatic DNA synthesis technology overcomes the limitations of traditional methods, giving scientists access to accurate complex DNA, quickly and reliably.

            View the press release.